The SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial [25] showed that sotagliflozin, an SGLT2i that also inhibits gastrointestinal SGLT1 to some extent, decreased the risk of death from cardiovascular causes or hospitalization and urgent visits for HF in patients with T2DM and recent hospitalization for worsening HF. This evidence concerns the gene SLC5A1 and hydrops fetalis.